| | Bites & Stings | Animal Bites
Glanders: Understanding This Rare Zoonotic Biothreat Pathogen
Glanders is a zoonotic disease caused by Burkholderia mallei, a Gram-negative bacillus that primarily affects equids (horses, donkeys, mules) but can infect humans through occupational exposure. Classified as a Tier 1 select agent due to its aerosol infectivity, low infectious dose, and high mortality if untreated, it represents a significant biothreat concern.
Transmission Pathways
- Direct contact with infected animal tissues and secretions (nasal, ocular, purulent exudate).
- Inhalation of infectious aerosols (laboratory, necropsy, slaughter settings).
- Inoculation through skin abrasions or mucous membranes.
- No documented human-to-human transmission (rare theoretical cases only).
Clinical Forms in Humans
- Localized cutaneous (most common): Pustular/nodular lesions at inoculation site ("farcy" if lymphangitic spread); ulcerate and heal with scarring.
- Pulmonary: Pneumonia, abscesses, pleural effusion; high mortality; may follow inhalation or hematogenous spread.
- Septicemic: Bacteremia, metastatic abscesses (spleen, liver, muscle), septic shock; fulminant, >90% mortality if untreated.
- Chronic: Recurrent abscesses, granulomatous lesions persisting months to years.
Equine Disease
- Nasal form: mucopurulent discharge, septal ulcers, nodules ("glanders nodules").
- Pulmonary form: pneumonia, nodules.
- Cutaneous form (farcy): lymphangitis, nodules along lymphatics.
- Diagnosis: Mallein test (intrapalpebral allergen), PCR, culture.
- Control: Test and slaughter; no vaccination; strict quarantine.
Human Diagnosis
- Culture: Definitive; B. mallei grows on standard media (24–48h); oxidase-positive, non-motile, non-lactose fermenter. BSL-3 required.
- PCR: Real-time assays targeting bimA, tssM; rapid, specific.
- Serology: Complement fixation, ELISA; cross-reactivity with B. pseudomallei (melioidosis).
- Imaging: CXR/CT for pulmonary/septicemic forms.
Treatment Regimens
- Acute/severe: IV meropenem (1g q8h) or imipenem + doxycycline (200 mg q12h) × 10–14 days.
- Eradication (oral): Doxycycline + TMP-SMX (160/800 mg q12h) × 3–6 months (prevents relapse).
- Alternatives: Ceftazidime, carbapenems, TMP-SMX monotherapy (mild cases).
- Post-exposure prophylaxis: Doxycycline 100 mg q12h × 21 days (high-risk exposure).
Infection Control
- Standard + contact + airborne precautions for pulmonary/septicemic cases.
- Laboratory: BSL-3; select agent registration (CDC/APHIS).
- Veterinary reporting mandatory (OIE notifiable).
Glanders is rare but high-consequence. Clinical suspicion in endemic areas or lab workers + rapid BSL-3 confirmation + prompt combination therapy saves lives.
Animal Bites - Related Articles
- New Jersey Animal Quarantine Regulations: Protecting Public Health
- Rabies Transmission to Children from Pets: Low Risk but Serious
- Rat Bites and Rabies: No Risk, But Other Infections Possible
- Bared: Definition, Meanings, and Usage Examples
- Bite Wound Management: When Suturing Is Appropriate vs. Contraindicated
- Bartholin's Glands: Anatomy, Infections (Bartholinitis), and Treatment
- Why Chewing Food Thoroughly Matters: 7 Science-Backed Benefits
